CPSI-1306

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

(±)-CPSI-1306 is a macrophage migration inhibitory factor (MIF) antagonist and can be used in studies about non-insulin-dependent diabetes mellitus (NIDDM) and the prevention of the deleterious cutaneous effects of acute and chronic UVB exposure.

(±)-CPSI-1306 is a macrophage migration inhibitory factor (MIF) antagonist and can be used in studies about non-insulin-dependent diabetes mellitus (NIDDM) and the prevention of the deleterious cutaneous effects of acute and chronic UVB exposure.(In Vivo):In mice, (±)-CPSI-1306 decreases their blood glucose levels and can be effective in treating non-insulin-dependent diabetes mellitus (NIDDM) as characterized by high serum levels of glucose and inflammatory cytokine. (±)-CPSI-1306-induced keratinocyte apoptosis is appreciated 30 minutes after a single UVB exposure. (±)-CPSI-1306-treated mice show a significant increase in expression of cleaved caspase-3 at 6, 24, and 48 hours following UVB exposure. (±)-CPSI-1306 reduces acute UVB-induced keratinocyte DNA damage and UVB-induced acute inflammation.

cpsi-1306; 2-(3-(2,4-Difluorophenyl)-4,5-dihydroisoxazol-5-yl)-1-morpholinoethan-1-one

Others

Other Targets

AddAB helicase-nuclease; RecBCD helicase-nuclease

——

——

1309793-47-2

310.3

C15H16F2N2O3

>98% (HPLC)

——

Fc1ccc(C2=NOC(CC(=O)N3CCOCC3)C2)c(F)c1

——

(-20℃)

With Ice Pack

≥ 2 years